NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced that long-term
data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of
median follow-up, triple-class-exposed patients with relapsed or refractory
multiple myeloma who were treated with TALVEY maintained high overall response
rates and durable responses, irrespective of whether they had received prior
T-cell redirection therapy. The company said 24-month overall survival rate of
67 percent was achieved with TALVEY 0.8 mg/kg biweekly dosing in the Phase 1/2
MonumenTAL-1 study.

TALVEY received FDA approval in August 2023 as a first-in-class GPRC5D-targeting
bispecific antibody for the treatment of adult patients with relapsed or
refractory multiple myeloma who have received at least four prior lines of
therapy, including a proteasome inhibitor, an immunomodulatory agent, and an
anti-CD38 antibody.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX